POLB — Poolbeg Pharma Share News
0.000.00%
Last trade - 00:00Significant POLB 001 Patent Granted in USA
Brief: Poolbeg Pharma Entered Into Exclusive 12-Month Option Agreement With Silk Road Therapeutics
Results for the year ended 31 December 2023
Brief: Poolbeg Pharma PLC Gets Notice Of Allowance For Significant POLB 001 Patent In United States
POLB 001 US Patent Update
Director/PDMR Shareholding
Director Share Purchase
Brief: Poolbeg Pharma Cathal Friel Currently Is Assuming Role Of Executive Chairman At Company Effective Immediately
Board Role Change and Launch of EIP
Brief: Poolbeg Pharma Says Further Data Showed Polb001's Potential In Cancer CRS
RSV AI Drug Candidate Analysis Update
Brief: Poolbeg Pharma Says Patrick Ashe Will Step Down From Board At End Of Nov
Directorate Change
Brief: Poolbeg Pharma Says Japanese Patent Office Notified Co Of Official Decision To Grant Poolbeg's Immunomodulator II Patent Application
Immunomodulator II patent granted in Japan
POLB 001 LPS Trial Data to be Presented at IUIS
POLB001 Data to be Presented at ASH Annual Meeting
Brief: Poolbeg Pharma Says Its Scientific Advisory Board Endorsed Influenza Drug Targets Identified In Its Ai-Led Drug Discovery Programme
SAB Endorses Influenza Drug Targets